News | August 04, 2011

First Multi-Site Study Evaluates Targeted Radiation Approach for Shorter, Safer Prostate Treatment

August 4, 2011—The first multi-institutional study evaluating a new form of radiation treatment for prostate cancer coupled with sophisticated real-time tumor tracking is now underway at the University of Michigan Health System in Ann Arbor, Mich. Principal investigator Daniel A. Hamstra, Ph.D., M.D., assistant professor, department of radiation oncology, along with 10 co-investigators, are evaluating the safety of shortened (hypofractionated) stereotactic body radiation therapy (SBRT) with Calypso Medical’s GPS for the Body technology, used for real-time tracking of cancerous tumors during prostate radiotherapy, and comparing it to conventional radiation treatment.

According to Hamstra and co-investigators, SBRT heightens the need for accurate, precise real-time tracking of prostate motion during radiation treatment. The delivery of larger, more concentrated radiation doses creates concern about exposing the surrounding healthy tissue to the same high doses, thereby increasing the potential for side effects such as rectal injury, impotence and difficulty urinating. Calypso Medical’s real-time tracking technology accurately and precisely tracks the location of the prostate to allow doctors to confidently deliver larger doses of SBRT, while lowering the total number of treatments.

“To a large extent, identification of prostate location has only been performed prior to the start of treatment without taking into account the motion of the prostate during treatment, yet precise targeting of the prostate gland during radiation is critically important in order to avoid delivering unintended radiation to healthy tissue,” said Hamstra. “This is the first multi-institutional study to incorporate use of the Calypso real-time tumor tracking technology, which allows us to significantly reduce the margin of healthy tissue around the prostate to prevent the development of unwelcome side effects. We are optimistic that use of the Calypso System in concert with a small number of dose-intensified treatment sessions may be a way to optimize SBRT.”

The multi-site study is testing whether a short-course, treatment regimen with continuous real-time evaluation of prostate motion is safe and effective for patients compared to conventional treatment. The 39-month Phase II study will enroll 66 patients, who will receive five 30-minute treatment sessions (fractions) of radiation with at least two days between each fraction. Each fraction size will be 7.4 Gray (unit of absorbed radiation dose) and the total radiation dose will be 37 Gray. The shortened five-fraction treatment will range from just 15-19 calendar days in comparison to conventional treatment protocol of 40-45 daily treatments, which takes eight-to-nine weeks to complete.

“The Calypso technology is critical because it provides the only real-time means to localize the prostate, providing needed information regarding motion that occurs due to normal bladder and bowel filling,” said Dale Litzenberg, Ph.D., co-investigator and clinical assistant professor, department of radiation oncology, University of Michigan. “With this information, we can use tighter treatment margins, which should lessen the risk for both acute and late toxicities. Combining Calypso with SBRT creates a treatment approach that allows patients to maintain their quality of life while spending significantly less time away from family and work.”

In addition to the University of Michigan, participating institutions include Washington University (St. Louis, Mo.); The Fox Chase Cancer Center (Philadelphia); Cedars Sinai Medical Center (Los Angeles), and Radiation Oncology Centers (Sacramento, Calif.).

“We are very encouraged by this multi-institutional study evaluating Calypso’s real-time tumor tracking for prostate SBRT, as this research will offer broad-based information to complement previous single-center studies with the same objectives,” said Lisa Levine, Ph.D., vice president, clinical and pre-market regulatory affairs for Calypso Medical. “Recent results from a single-center study reported favorable toxicity and quality-of-life outcomes in urinary, rectal and sexual function. These study results and others suggest that the much shorter delivery schedule combined with the potential for a more efficacious treatment makes SBRT a very appealing option for the right patient.”

Calypso Medical will highlight the use of real-time tracking during prostate cancer radiotherapy and investigational use in lung cancer at the upcoming 2011 Joint American Association of Physicists in Medicine (AAPM) and the Canadian Organization of medical Physicists (COMP) meeting, July 31-August 4 at the Vancouver Convention Centre (Booth #1131).
 
For more information: www.calypsomedical.com

Related Content

Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...